Earnings call transcript: Global Medical REIT Q2 2025 shows EPS miss, revenue beat

Published 06/08/2025, 15:08
Earnings call transcript: Global Medical REIT Q2 2025 shows EPS miss, revenue beat

Global Medical REIT Inc. (GMRE) reported its Q2 2025 earnings, revealing a mixed performance. The real estate investment trust posted a revenue of $37.9 million, surpassing forecasts of $35.39 million, marking a 7.09% positive surprise. However, the company reported an earnings per share (EPS) of -$0.01, missing expectations of $0.01 by a significant margin. Following the earnings release, the stock dipped 2.37% to $6.75, though it showed a modest pre-market recovery of 0.74%. With a market capitalization of $454.83 million and an impressive gross profit margin of 99.74%, GMRE maintains strong operational efficiency. InvestingPro analysis reveals 7 key investment tips for GMRE, including positive indicators for future profitability.

Key Takeaways

  • Revenue exceeded forecasts by 7.09%, reaching $37.9 million.
  • EPS fell short of expectations, registering a -200% surprise.
  • Occupancy rates dropped due to lease expirations and rejections.
  • Dividend reduced from $0.21 to $0.15 per share.
  • Stock fell 2.37% post-earnings but showed slight pre-market recovery.

Company Performance

Global Medical REIT’s Q2 2025 performance was marked by a revenue beat but a notable miss on EPS. The company’s occupancy rate declined to 94.5% from Q1, primarily due to lease expirations and rejections at key properties. Despite these challenges, the company successfully re-tenanted its Beaumont, Texas facility, contributing to an expected year-end occupancy rate of over 95%. According to InvestingPro data, GMRE maintains a healthy current ratio of 1.37, indicating strong ability to meet short-term obligations. The company’s beta of 1.19 suggests moderate market sensitivity.

Financial Highlights

  • Revenue: $37.9 million, up from the forecasted $35.39 million.
  • Earnings per share: -$0.01, missing the forecasted $0.01.
  • Dividend: Reduced from $0.21 to $0.15 per share.
  • Dividend coverage dropped to 79% on an FAD basis.

Earnings vs. Forecast

Global Medical REIT reported an EPS of -$0.01, falling short of the forecasted $0.01, resulting in a -200% surprise. Revenue, however, surpassed expectations with a 7.09% surprise, reaching $37.9 million.

Market Reaction

The stock price declined by 2.37% to $6.75 following the earnings announcement, reflecting investor disappointment in the EPS miss and dividend reduction. Despite this, a pre-market increase of 0.74% suggests some investor optimism, possibly due to the revenue beat and positive operational updates. InvestingPro Fair Value analysis indicates that GMRE is currently undervalued, presenting a potential opportunity for value investors. The stock maintains an attractive dividend yield of 8.89%, significantly above the industry average, though investors should note the recent dividend reduction.

Outlook & Guidance

Looking forward, Global Medical REIT aims to renew portions of its credit facility due in 2026 and target a leverage ratio below 40%. The company also plans potential asset recycling of $50-100 million and continues to work with Heitman JV for future investments. For deeper insights into GMRE’s financial health and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro, covering detailed analysis of 1,400+ top US stocks.

Executive Commentary

"We want to get the refinancing of the line and the terminal done," said CEO Mark Decker, highlighting the company’s focus on financial stability. Decker also mentioned, "We’re going to be looking at some capital recycling," indicating a strategic approach to asset management.

Risks and Challenges

  • Lease expirations and rejections leading to lower occupancy.
  • Reduced dividend and coverage could impact cash flow.
  • Potential refinancing challenges amid market volatility.
  • Competition in the medical office building market.

Q&A

During the earnings call, analysts inquired about the company’s balance sheet strategy and potential refinancing plans. Executives confirmed a consistent occupancy target around 95% and discussed asset disposition and reinvestment strategies.

Full transcript - Global Medical REIT Inc (GMRE) Q2 2025:

Conference Operator: Good day, everyone, and welcome to today’s Global Medical Rights Second Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note this call may be recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Jamie Barber, Global Medical Rights General Counsel.

Please go ahead.

Jamie Barber, General Counsel, Global Medical REIT: Good morning, everyone, and welcome to Global Medical REIT’s Second Quarter twenty twenty five Earnings Conference Call. My name is Jamie Barber, and I’m Global Medical REIT’s General Counsel. On the call today are Mark Decker, Jr, Chief Executive Officer Alfonso Leon, Chief Investment Officer Danica Holli, Chief Operating Officer and Bob Kieran, Chief Financial Officer. Statements or comments made on this conference call may be forward looking statements. Forward looking statements may include, but are not necessarily limited to, financial projections or other statements of the company’s plans, objectives, expectations or intentions.

These matters involve certain risks and uncertainties. Company’s actual results may differ significantly from those projected or suggested from any forward looking statements due to a variety of factors, which are discussed in detail in our SEC filings. Additionally, on this call, the company may refer to certain non GAAP financial measures. You can find a tabular reconciliation of these non GAAP financial measures to the most currently comparable GAAP numbers in the company’s earnings release and in filings with the SEC. Additional information may also be found on the Investor Relations page of the company’s website at www.globalmedicalreit.com.

I would now like to turn

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: the call over to Mark. Thank you, Jamie. Welcome, everyone, and thanks for joining us today. It’s my pleasure to provide our quarterly update as the new CEO of Global Medical REIT. To begin, I have a few thank yous.

First, I’d like to thank the Board for placing their confidence in me to lead our business into the next chapter. I’d also like to thank Jeff Busch for his work as the company’s founder. Jeff built a strong foundation that we will take to the next level. And finally, I want to thank our talented team here for their hard work, grace and efforts to keep things moving during the transition that started in January when we announced the CEO transition plan. I’m excited to work together with them to reimagine our business and unlock new opportunities for growth and value creation.

And they are excited to get back in gear. So it’s a great time for our company. I will now turn the call over to Danica Holley, our Chief Operating Officer. Danica?

Danica Holli, Chief Operating Officer, Global Medical REIT: Thank you, Mark. As many of you are aware, earlier this year, we successfully re tenanted our Beaumont, Texas facility with Christus Health as our new tenant. I’m pleased to announce that as of May, Christus is fully operating in the facility and is paying rent. This is a huge success story given the status of the previous tenant, Steward Healthcare, and an example of our team’s ability to navigate obstacles to a successful conclusion.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: More broadly on the portfolio,

Danica Holli, Chief Operating Officer, Global Medical REIT: as of 06/30/2025, our occupancy stood at 94.5%, which is down from the first quarter primarily due to the expiration of the lease at our 50,000 square foot Aurora, Illinois property and the rejection of the master lease at our 60,000 square foot East Orin, New Jersey property related to the Prospect Medical bankruptcy. We touched on both of these in prior calls, but I’d like to offer a little more color. In Aurora, this was a healthcare administrative building adjacent to one of the system’s new outpatient facilities. We purchased this building pre COVID with an expectation that the system would expand, and unfortunately COVID changed the system’s utilization of the administrative space. We are currently looking to sell or re tenant this facility.

On the flip side, after almost two years of negative cash flows, the developments at East Orange are positive. We now have control over the space, which is 40% occupied and are working directly with former subtenants and prospective tenants, including the new adjacent hospital operator. We expect this property to recover to stabilized occupancy of over 90% in the next twenty four to thirty six months. Turning to our leasing activity, we expect total occupancy to end the year over 95%, which includes 150,000 square feet of new leases, 130,000 of which are complete. Regarding CapEx and leasing commissions, year to date spend is $5,200,000 and our guidance for the full year is between 12,000,000 to 14,000,000 so we are well positioned.

I would now like to turn the

Alfonso Leon, Chief Investment Officer, Global Medical REIT: call over to Alfonso to discuss our investments. Alfonso? Thank you, Danica. During the quarter, we completed the acquisition of a five property portfolio of outpatient medical real estate, which brings our total acquisition volume for 2024 and 2025 to approximately $150,000,000 at a blended going in cash yield of 8.5%. While we are ecstatic about the cash yields, we are even more excited about our ability to find differentiated investment opportunities.

First and foremost, we were able to achieve portfolio discounts with our execution capabilities, including our balance sheet strength when lending for portfolios was unavailable. On the real estate side, we were able to achieve wide discounts to replacement cost, and we believe in place rents are more than 30% below market, which will allow us to grow future rents at faster than market rates, while still providing a significant value proposition to our tenants. Based on our proprietary data, portfolio volumes, which averaged $300,000,000 per quarter from 2022 to 2024 spiked in the 2025 to $2,100,000,000 over seven times recent levels, and we expect this level of activity to continue due to the large activity in 2020 and 2021 by levered short term owners. We are excited to compete in this market because in our experience, a flood of opportunities like this offers inefficiencies that we can benefit from with our proven middle market expertise, track record and reputation as a great counterparty. With that, I’d like

Bob Kieran, Chief Financial Officer, Global Medical REIT: to turn the call over to Bob. Thank you, Alfonso. As we look at the remainder of 2025, our highest priority on the balance sheet is to renew the portions of our credit facility that are coming due in 2026, namely the revolver and our $350,000,000 term loan. We are in active discussions with our lending group regarding renewal, expect to complete the renewal during the 2025. We value the strong relationships we have with our current bank lending group and over time we are looking to expand our lender relationships to potentially include longer term debt providers such as insurance companies.

By diversifying our lender and tenor mix, we will improve the quality of our earnings and broaden our access to debt capital. As reported earlier this year, the company lowered its second quarter twenty twenty five dividend from zero two one dollars per share to $0.15 per share. We view this as the rightsizing of our dividend as our dividend coverage went from 110% during the 2025 to 79% during the 2025 on

Jamie Barber, General Counsel, Global Medical REIT: a FAD basis. And as you’ll see

Bob Kieran, Chief Financial Officer, Global Medical REIT: in our supplemental, when we say FAD, we are talking about our cash flow after all capital expenditures and leasing commissions. Additionally, the dividend reduction is expected to generate approximately $17,000,000 per year that can be allocated to our best ideas. Given the dearth of the equity capital markets in recent years, we are looking at alternative sources for growth. The rightsizing of our dividend is the most important action we took in this regard and we will continue asset recycling. We have identified several assets that are candidates for capital recycling.

Our portfolio contains organic growth opportunities that can sustain us until the equity capital markets open up again and look forward to what is to come under Mark’s leadership. With that, I’ll turn the call back over to Mark for final comments.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Thanks, Bob. I’m happy to say I know many of those on this call, but for those who don’t know me, I have almost thirty years of capital markets, real estate and leadership experience, nearly twenty years in investment banking, building teams to serve middle market real estate companies that were undergoing some growth and or transition, and seven years in the C suite at Center Space, mostly as CEO. Center Space was another smaller public real estate company that needed to meaningfully reposition their business. If nothing else that makes me experienced and hopefully a little wise. I sought out this role because I love the work of delivering results and communicate them clearly to our three key audiences, our team, our customers and the capital markets.

If we can do this, be formidable in our niche, post results and communicate well, we’ll be in a great spot. So that’s why I’m here and happy to be underway. It’s early days for me, but you can expect that we will fully review our portfolio with an eye towards identifying opportunities. We’ll also be working to take our 100% unsecured balance sheet and turning it into more of a competitive advantage with the establishment of a long debt maturity lateral. And we’ll be looking inwards to our team to see how and where we can improve, all with the goal of owning the middle market healthcare real estate space, providing great results to our business owners and growth for our team.

Lastly, I hope you’ll notice our supplemental in this call, we’re seeking to be more transparent and easy to evaluate and understand, starting with improved clarity of our disclosure. We understand these are table stakes as a smaller public company. If you have suggestions, as Ross Perot says, we’re all ears. Please call or send an e mail with your suggestions. Thank you for listening.

And operator, please open the call for Q and A.

Conference Operator: Thank you. Our first question will come from Austin Wurschmidt with KeyBanc Capital Markets. Your line is open.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: Hey, good morning everybody. And welcome to the call, Mark. There was a little bit of a technical issue, so sorry if I missed this. But I guess, Mark, could you just lay out kind of what the immediate strategic priorities are for you and that you think that the company could be doing differently on a go forward basis?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Sure. Yes, thanks, Austin. That was not me playing saxophone. But can you hear me okay?

Juan Sanabria, Analyst, BMO Capital Markets: Yes, I can hear you fine.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Okay, thanks. Yeah, immediate strategic priorities are to come together on a strategy with the with the team and the board. We have a bunch of good ingredients, think in the business, as we sit today, and I think we can organize those a little bit more thoughtfully. Obviously, we want to get the refinancing of the of the line and the terminal and a done. So, really good about where we are on that, but nothing’s done until it’s done.

And then we’re going to be looking at some capital recycling. So, those are the immediate priorities.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: I appreciate that. And then, I think, Bob, you kind of outline, continue asset recycling and that you’ve identified some assets. Can you could you just give us a sense of what types of assets these are from an occupancy perspective or whether there’s a capital need and where you think you can sell assets as it sounds like there’s a little bit of a pickup in liquidity in the transaction market?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Yeah, I’ll take that one. I’ll say, ideal candidates would be the lowest yielding or best priced thing. So if you could imagine things that had long term leases with high grade tenants, those would probably be first to go. And then I’d say on the other side, to the extent we have assets that we don’t believe in long term after portfolio review, which which we are undergoing, you know, we’ve got this new car smell for a little bit, we’re going to take it for a ride. And so if there’s anything that doesn’t look long term now, we’ll work to get rid of that as well.

I don’t honestly see a ton of that so far. But so I’d say it’s more offensive capital recycling in mind, maybe a little bit of deleveraging, maybe a little bit of enhancing cash flows while taking advantage of some of those high quality assets that are well bid today.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: So where do you think you can ultimately what type of spread do you ultimately think you can reinvest those proceeds? Alfonso, I think you referenced sourcing assets at wide discounts, replacement cost with really attractive mark to market opportunities. Are those out there? And what does that spread look like on a going in basis? And then I’ll yield the floor.

Thanks.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Sure. So, the market is there’s a range of cap rates in the market. The higher quality stuff is trading in the low and sometimes sub-six cap. But the bulk of the market is trading in the mid-six to higher-six. And there’s a good chunk of deals that are trading north of seven.

And selectively, there are deals that are higher than mid sevens. So, we’ve always played in that higher range or the cap rate range. And with the flood of deals that have come to market, there’s a lot of opportunities out there that fit in that bucket.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Yeah, I just add to that. I think we’re using the word quality in a way that is market convention. I mean, I think something that’s sub five that grows at two is not as good as something that’s 7.5 and grows at two. And what I think can be observed based on historical facts is that some of those really tight yields don’t actually grow more. And in many instances, your landlord probably has more leverage over you than maybe otherwise.

So it’s our contention. And I think Alfonso and his team have done a fantastic job over the last several years of doing this well of finding good properties that yield more, which in my view are higher quality and best better risk adjusted return. So we’re going to lean into where we have been, because I think it’s worked well for us. And then we’re going to be working very hard on producing, better than average per share FFO growth, which we got to put a plan and a formula together to do that. But I think this is an area where kind of the law of small numbers helps us.

Dollars 15,000,000 is 1% of enterprise value and $720,000 is a penny. So we can get this thing going, I think, without moving heaven and earth. And we are buying in my estimation that and what we just recently purchased the last bit of that portfolio is fantastic deal in terms of price per pound opportunity for rent upside, great tenancy. So we’re going try to do more like that. Those are hard to find.

We don’t need to find a ton of them to make a difference.

Austin Wurschmidt, Analyst, KeyBanc Capital Markets: That’s helpful. Thanks for the time.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Thank you.

Conference Operator: Our next question comes from Juan Sanabria with BMO Capital Markets. Your line is open.

Wes Golladay, Analyst, Baird: Hi, good morning. Just curious what initial thoughts on where leverage is targeted to be recognizing it sounds like whatever strategic review is more ongoing versus finalized, but just curious on how we should think about leverage over medium term.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Yeah. I mean, I think ideally, we’d like to have a balance sheet that has more capacity for growth. And in my mind, means stake around, sub 40% or sub six times would be a great spot. I think if you look at our pricing grid from the banks, they would say we’re nearly but not quite investment grade. I think if you were to talk to the private placement community, they would say we’re cuspy, but I think it’s more probably size than quantum of debt.

So I mean, obviously, we have relatively more debt for a public company and a lot less debt than our private peers would have. I mean, we’re we sleep like babies, we’ve got great cash flows. We will stretch out our maturity ladder and that’ll feel better, you know, four times that if it expires tomorrow is is worse than nine times debt if your weighted average maturity is seven years from now. We’re not at either of those extremes. But we do have a large maturity obviously coming and we’re working on that.

We have all the confidence that that’ll be achievable in the near term.

Wes Golladay, Analyst, Baird: And just a quick follow-up on that. Would that be inclusive, the six times of preferreds?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Man, I thought we were going to stay off this religious bait for today. But, but we’ll go let’s go there. But preferred in my opinion doesn’t have a redemption date. So it is more like equity than debt. And I know that not everyone agrees with that.

But, for the time being and giving our small size and cost of capital, the preferred is something we can look at. It’d be a great use of proceeds down the road if we had a cost of capital that made sense. But today, forever is a long time. So if you’re going to call it debt, then I’d say you’ve added to our weighted average maturities. And if you’re going to call it equity, then I’d say I agree.

But no, my six doesn’t include that. But I understand that the equity buyers will think that way and we’re mindful of that.

Gaurav Mehta, Analyst, Alliance Global Partners: Fair enough. And just on the occupancy perspective,

Wes Golladay, Analyst, Baird: I think you shared some thoughts, apologies for missing the numbers on kind of how you expect occupancy in the portfolio to trend. And the general trend has been one that seems a modest slippage as some leases expired and retention levels just naturally had some churns. But just curious on how we should think about that going forward, any known large move outs. As part of that answer, if you don’t mind, with the Beaumont facility, what’s the incremental we should be modeling third quarter to second quarter on that asset specifically?

Danica Holli, Chief Operating Officer, Global Medical REIT: So, hi, Juan. On occupancy, I think you can think of us in that 95 and above range. We’re consistently seeing trends with our tenants to re lease at those levels. So I think consistency and occupancy is what you should look for. There will be episodic downturns that are followed by re leasing.

So it can be a little bit bumpy, but overall, I think that’s the way to think of it. I’m going to actually turn to Bob to talk about the modeling for how we thought of CHRISTUS.

Bob Kieran, Chief Financial Officer, Global Medical REIT: For the Beaumont asset, for the second quarter, they fully occupied beginning in mid May. So, the second quarter, you’ll have May and June. So, again, it’ll be a modest pickup in the third quarter from a run rate perspective,

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: all of which was in our guidance.

Jamie Barber, General Counsel, Global Medical REIT: Got it.

Conference Operator: Our next question comes from Wes Golladay with Baird. Your line is open.

Jamie Barber, General Counsel, Global Medical REIT0: Hey, good morning, everyone. Maybe just sticking with the quarter to quarter changes. We also have a pickup in reimbursed costs in the third quarter, or would the move outs impact that at all? How should we think about unreimbursed costs going forward?

Bob Kieran, Chief Financial Officer, Global Medical REIT: So Wes, there really wasn’t anything in particular of note relative to rental revenue versus the reimbursed costs. From an overall NOI perspective, the way that the trend was consistent with where we were forecasting. And there really wasn’t anything significant or unusual from the dynamic between reimbursed costs and the rental revenue side.

Jamie Barber, General Counsel, Global Medical REIT0: Okay. And then you mentioned tackling the balance sheet, I think, in the fourth quarter. Were you going to do both, I guess, term loans and private placements? Or is it an and or? Or how are you thinking about that?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: To be determined, for sure, we’re going to refi the term loan A and the revolver and how exactly that gets done isn’t set in stone just yet.

Jamie Barber, General Counsel, Global Medical REIT0: Okay. And then G and A for the back half of the year, should it be comparable, I guess, on a quarterly basis to what we saw in the second quarter outside the onetime items?

Bob Kieran, Chief Financial Officer, Global Medical REIT: Yes, there should be. Yeah, that’s a good run rate from a G and A perspective. That’s what we’re flagging those outliers from the transition costs, backing those down from both stock comp and the cash G and A will align it.

Jamie Barber, General Counsel, Global Medical REIT0: Okay, thanks for the time, everyone.

Conference Operator: Our next question comes from Gaurav Mehta with Alliance Global Partners. Your line is open.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Yes. Thank you. Good morning. I wanted to go back to

Gaurav Mehta, Analyst, Alliance Global Partners: your comments around asset recycling. Hoping to get some more color on what kind of size of disposition are you guys looking at? And then does the asset recycling depends on you finding the right acquisition targets? Or you would consider selling and loading leverage in the near term?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Rob, just your line is a little faint. Did you say what kind of acquisitions are we looking for?

Gaurav Mehta, Analyst, Alliance Global Partners: My question was what kind of size of dispositions are you looking at? And then would you consider selling and lowering leverage in the near term or the disposition depends on finding the right acquisition targets?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Got it. So, I mean, don’t want to I think our goal would be, call it 50,000,000 to $100,000,000 But if we don’t get prices we like, we may not be selling. And then how those proceeds got redeployed would be likely a mix of some debt repayment and some new investment. I mean, at a minimum, we’d pay down debt that would probably be a good use, but we probably have some other ideas as well.

Gaurav Mehta, Analyst, Alliance Global Partners: Okay. And then Mark, as you look at the next chapter for the company as far as acquisition and the portfolio mix, do you expect any changes in specialty type and provider type or you want to stick with where the portfolio is, as far as that mix is concerned?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: I said, we generally like the mix the way it is. I mean, they don’t move around.

Alfonso Leon, Chief Investment Officer, Global Medical REIT: Agree. So, know, we’ve always been opportunistic, we always try to find the best value in the market. MOBs are by far the largest that is the asset type that has the largest supply in the market. But we’ve been pretty good at finding inpatient and playing in that space. So, you know, I would assume that going forward, the portfolio mix should stay roughly consistent.

Gaurav Mehta, Analyst, Alliance Global Partners: Okay. Thank you. That’s all I had.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Thank you.

Conference Operator: Our next question comes from John Massocca with B. Riley Securities. Your line is open.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Good morning, everyone. So maybe with kind

Juan Sanabria, Analyst, BMO Capital Markets: of cost of capital in mind, you talked a little bit about capital recycling as a way to kind of fund future investments. How are you thinking about JVs, either the one you currently have in place or maybe even future, different de novo JVs? Just curious your thoughts there.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Yeah, good morning. Good question. We would we’d like to grow the Heitman JV that they’re a thoughtful and disciplined MOB investor with over twenty years in the space. And they like we believe in the secondary, tertiary and quaternary investments with strong systems or practice groups that have dominant market share. So, that’s a good alignment of, say, view of the world.

And I think there are other potential capital structures we could look at where we can take what we believe is something of value, which is our ability to underwrite these smaller opportunities and deliver that to people that maybe don’t have that skill. So how that takes shape, if it takes shape to be determined, but it’s certainly something on our Board, if you will.

Juan Sanabria, Analyst, BMO Capital Markets: And then I guess, I know it’s little bit unfair because it was kind of put in place earlier this year, but given the amount of activity you’re seeing in the space in 2Q, any reason that JV hasn’t been more active?

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: No. I mean, if there’s one deal you like among one, and that one’s worth doing. And if there’s one among 100, that one’s worth doing. I mean, we have to be disciplined. And they are disciplined with us in that regard.

So they’re picky and we’re picky. And when it’s right, we’ll do it. And if it’s not, we don’t have any unnatural reason to do anything with Hyphen, and they certainly don’t either. They’re fiduciaries and so are we.

Juan Sanabria, Analyst, BMO Capital Markets: That’s fair. And then maybe on a much smaller level, as I think about the East Orange kind of success leasing up there, can you remind us maybe what the impact run rate numbers is going to be from that lease up? And if there is any impact, what timing you’re expecting?

Bob Kieran, Chief Financial Officer, Global Medical REIT: So the old run rate on that building was roughly about $1.2.1300000.0 ABR. And again, as we talked about, that’s been a cash flow drag over the last couple of years. And so what we’re seeing right now is we’ve gotten the building to 40% or so from an occupied status. And as we work at that level, we start to, again, turn the corner and break even relative to the property, and over time build that base and increase that to that eighty-ninety percent occupancy. But from an overall perspective, a sizing, just to give you the context, that’s where it was.

It was around kind of, again, from a contribution was about 1,000,000. Point And again, we’re on the trying to get on the path back toward that level.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: I do think that John, this is something we’ve been talking about. As we’ve been out with investors, that is all everything I’m telling you is publicly available, but it requires work to put it together. And I think there’s a perception to the extent people are paying attention about ’26 earnings that we have a big hit coming from this refi. And we will absolutely refi at a much higher rate. We currently have so for locked at 135 and it’s obviously at $4.35.

But when you consider that we weren’t getting cash flow really for much of any in ’25 and we will get some of that direct in from East Orange and we will have the full impact of Christus and the forward curve is looking pretty good. And we did make some acquisitions. Our year over year kind of FAD and FFO are actually going to be, I think, pretty good. We’re not here to give ’26 guidance. But I do think that’s something that’s a little bit misunderstood about us today.

Okay. Appreciate that color.

Juan Sanabria, Analyst, BMO Capital Markets: That’s it for me. Thank you.

Conference Operator: It appears we have no further questions at this time. I’ll turn the program back to Mark for any closing remarks.

Mark Decker, Jr, Chief Executive Officer, Global Medical REIT: Super. Well, we appreciate everyone’s time and interest, and have a great day. Thank you.

Conference Operator: This concludes today’s program. Thank you for your participation and you may disconnect at any time.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.